Acetyl-NFE4 (K43) Antibody

What is the Acetyl-NFE4 (K43) antibody and what is its target?

The Acetyl-NFE4 (K43) antibody is a polyclonal antibody produced in rabbits that specifically recognizes the acetylated form of NFE4 at lysine 43. NFE4 (Nuclear Factor, Erythroid 4) is a transcription factor that plays a crucial role in regulating gene expression, particularly in the erythroid lineage. This antibody enables researchers to detect and study post-translational modifications of NFE4, specifically acetylation at the K43 position, which may impact its activity and influence downstream gene regulation processes .

Most commercially available Acetyl-NFE4 (K43) antibodies are generated using synthesized peptides derived from human NFE4 protein sequence surrounding the acetylation site of K43 as immunogens . They are primarily validated for use in human samples, though some products claim cross-reactivity with rodent samples.

What are the standard applications for Acetyl-NFE4 (K43) antibody?

The Acetyl-NFE4 (K43) antibody has been validated for multiple applications, with Western blot (WB) and ELISA being the most common. Based on product specifications:

For Western blot applications, researchers should start with a 1:1000 dilution and optimize based on signal intensity and background levels. The observed band size for acetylated NFE4 is approximately 19 kDa .

What is the biological significance of NFE4 acetylation?

NFE4 forms the stage selector protein (SSP) complex with the ubiquitous transcription factor CP2, which is involved in preferential expression of gamma-globin genes in fetal erythroid cells . NFE4 has two isoforms resulting from alternative translation initiation:

• Long isoform (22 kDa): Acts as an activator

• Short isoform (14 kDa): Functions as a repressor of gamma-globin gene expression

Acetylation at K43 is likely to influence NFE4's activity and its interactions with other proteins in the SSP complex, potentially affecting downstream gene regulation. Research using this antibody can help elucidate the role of this specific modification in cellular signaling pathways and disease mechanisms, particularly in areas such as epigenetics, cancer biology, and cell signaling .

How should I prepare samples for optimal detection of acetylated NFE4?

For effective detection of acetylated NFE4, consider the following methodological approach:

• Cell/Tissue Selection: NFE4 is specifically expressed in fetal liver, cord blood, bone marrow, and erythroid cell lines like K562 and HEL that constitutively express fetal globin genes . These are optimal sources for studying NFE4 acetylation.

• Lysate Preparation:

  • Use RIPA buffer supplemented with deacetylase inhibitors (e.g., TSA, nicotinamide) to preserve acetylation status

  • Include protease inhibitors to prevent protein degradation

  • Keep samples on ice during processing to minimize deacetylation

• Protein Quantification: Ensure equal loading by accurate protein quantification methods (BCA or Bradford assay)

• Sample Storage: Store prepared lysates at -80°C in single-use aliquots to avoid freeze-thaw cycles that can degrade proteins and reduce acetylation signals

What controls should I include when using Acetyl-NFE4 (K43) antibody?

• Positive Control: Lysates from cells known to express acetylated NFE4, such as AD-293 cells, which have been validated in Western blot applications with this antibody

• Negative Controls:

  • Primary antibody omission control

  • Samples treated with deacetylase enzymes (HDAC/SIRT family) to remove acetylation

  • Non-specific IgG control at the same concentration as the primary antibody

• Validation Controls:

  • Blocking peptide competition assay using the synthetic acetylated peptide used as immunogen

  • Comparison with total NFE4 antibody to assess proportion of acetylated protein

• Loading Control: Use appropriate housekeeping proteins (β-actin, GAPDH) for normalization

These controls will help validate specificity and ensure reliable interpretation of results.

How can I optimize Western blot conditions for Acetyl-NFE4 (K43) detection?

Optimization of Western blot conditions is crucial for specific detection of acetylated NFE4:

• Sample Preparation:

  • Load 20-50 μg of total protein per lane

  • Use fresh DTT or β-mercaptoethanol in sample buffer

• Gel Electrophoresis:

  • Use 12-15% polyacrylamide gels for optimal resolution of the 19 kDa band

  • Include molecular weight markers that cover the 10-25 kDa range

• Antibody Dilution Optimization:

  • Start with the recommended 1:500-1:2000 dilution

  • Perform a dilution series to determine optimal concentration

  • Dilute in buffer containing 1-5% BSA or non-fat dry milk to reduce background

• Incubation Conditions:

  • Primary antibody: Overnight at 4°C or 2 hours at room temperature

  • Secondary antibody: 1 hour at room temperature

  • Include 0.05-0.1% Tween-20 in wash buffers

• Detection System:

  • ECL systems are typically sensitive enough for detection

  • For low abundance, consider enhanced chemiluminescence substrates

• Membrane Type:

  • PVDF membranes generally provide better sensitivity than nitrocellulose for acetylation-specific antibodies

What are common issues when detecting acetylated NFE4 and how can they be resolved?

When troubleshooting, always include a systematic approach that changes only one variable at a time to identify the specific issue.

How can I quantify changes in NFE4 acetylation levels across different experimental conditions?

Quantification of acetylation levels requires careful normalization and analysis:

• Densitometric Analysis:

  • Use software like ImageJ, Image Lab, or specialized Western blot analysis software

  • Define regions of interest consistently across all samples

  • Subtract background signal from adjacent areas

• Normalization Strategy:

  • Primary normalization: Normalize acetylated NFE4 signal to total NFE4 protein level

  • Secondary normalization: Use housekeeping proteins (β-actin, GAPDH) to normalize for loading differences

  • Calculate the ratio of acetylated NFE4 to total NFE4 for each condition

• Statistical Analysis:

  • Perform experiments in biological triplicates

  • Use appropriate statistical tests (t-test for two conditions, ANOVA for multiple conditions)

  • Report fold changes relative to control conditions

• Validation:

  • Confirm changes using complementary techniques like immunoprecipitation followed by acetyl-lysine detection

  • Consider mass spectrometry for absolute quantification of acetylation stoichiometry

How can I design experiments to investigate the functional impact of NFE4 acetylation?

To elucidate the functional significance of NFE4 acetylation at K43, consider these experimental approaches:

• Site-directed Mutagenesis:

  • Generate K43R mutant (prevents acetylation but maintains positive charge)

  • Generate K43Q mutant (mimics constitutive acetylation)

  • Compare activity of wild-type vs. mutants in reporter assays

• Acetylation/Deacetylation Enzyme Identification:

  • Screen HAT (Histone Acetyltransferase) inhibitors to identify enzymes responsible for K43 acetylation

  • Test HDAC/SIRT inhibitors to identify deacetylases acting on K43

  • Perform co-immunoprecipitation to detect physical interactions with acetylation machinery

• Functional Readouts:

  • Measure gamma-globin expression as a downstream target

  • Assess NFE4 DNA binding capacity with or without acetylation

  • Evaluate interaction with CP2 and formation of the SSP complex

• Dynamic Regulation:

  • Monitor changes in K43 acetylation during erythroid differentiation

  • Assess response to stimuli that affect globin gene expression

  • Compare acetylation patterns in fetal vs. adult erythroid cells

Can Acetyl-NFE4 (K43) antibody be used for chromatin immunoprecipitation (ChIP) studies?

While the Acetyl-NFE4 (K43) antibody is primarily validated for Western blot and ELISA, researchers may adapt it for ChIP applications with careful optimization:

• Preliminary Verification:

  • Confirm antibody specificity in your cell system via Western blot

  • Demonstrate enrichment of acetylated NFE4 via immunoprecipitation

• ChIP Protocol Adaptation:

  • Increase antibody amount (typically 5-10 μg per ChIP reaction)

  • Optimize chromatin shearing conditions (aim for 200-500 bp fragments)

  • Include specific controls (IgG, input, positive locus control)

• Target Validation:

  • Focus initial ChIP-qPCR on well-established NFE4 binding sites in gamma-globin promoters

  • Include negative control regions where NFE4 is not expected to bind

  • Compare binding patterns of total NFE4 versus acetylated NFE4

• Analysis Considerations:

  • Calculate percent input and fold enrichment over IgG

  • Compare acetylated NFE4 binding with total NFE4 occupancy

  • Consider ChIP-seq for genome-wide binding profile if preliminary results are promising

• Technical Limitations:

  • Be aware that polyclonal antibodies may show batch-to-batch variation

  • Confirm specificity with blocking peptide competition in ChIP experiments

  • Consider collaborative validation with mass spectrometry

How does NFE4 acetylation interact with other post-translational modifications and regulatory mechanisms?

Investigating the interplay between NFE4 acetylation and other regulatory mechanisms requires integrative approaches:

• PTM Crosstalk Analysis:

  • Examine potential phosphorylation sites near K43 that might affect acetylation

  • Investigate whether K43 acetylation affects ubiquitination and protein stability

  • Study methylation sites that might compete with K43 acetylation

• Multimodal Detection:

  • Sequential immunoprecipitation with acetyl-specific and phospho-specific antibodies

  • Mass spectrometry analysis to identify multiple PTMs on the same NFE4 molecule

  • Proximity ligation assays to detect co-occurrence of modifications

• Regulatory Mechanisms:

  • Investigate how acetylation affects NFE4 subcellular localization

  • Determine if K43 acetylation alters protein-protein interactions using co-IP experiments

  • Assess impact on protein half-life through cycloheximide chase experiments

• Systems Biology Approach:

  • Integrate acetylation data with transcriptomic profiles

  • Map acetylation changes to signaling pathway activation

  • Model the hierarchical organization of NFE4 modifications

What is the potential significance of NFE4 acetylation in hemoglobinopathies?

Given NFE4's role in gamma-globin gene regulation, investigating its acetylation has potential implications for hemoglobinopathies:

• Fetal Hemoglobin Induction:

  • If K43 acetylation enhances NFE4's ability to activate gamma-globin, modulating this modification could be therapeutic

  • Compare acetylation levels in patients responding to HbF-inducing drugs like hydroxyurea

• Sickle Cell Disease and Beta-Thalassemia:

  • Determine if acetylation status differs in erythroid cells from patients versus healthy controls

  • Assess whether acetylation of NFE4 correlates with disease severity or response to treatment

• Drug Development Targets:

  • Identify specific HDACs or HATs that regulate NFE4 K43 acetylation

  • Screen for small molecules that modulate these enzymes to affect gamma-globin expression

  • Develop assays using the Acetyl-NFE4 (K43) antibody to screen compound libraries

• Gene Therapy Considerations:

  • Incorporate acetylation-mimicking NFE4 variants in gene therapy approaches

  • Combine NFE4 modulation with other globin regulators for synergistic effects

Understanding the molecular mechanism of NFE4 acetylation at K43 could potentially provide new avenues for therapeutic intervention in hemoglobinopathies.

How can researchers integrate Acetyl-NFE4 (K43) antibody data with other epigenetic markers?

Integrating NFE4 acetylation data with broader epigenetic landscapes can provide comprehensive insights:

• Multi-omics Integration:

  • Combine Acetyl-NFE4 ChIP-seq with histone modification ChIP-seq (H3K27ac, H3K4me3)

  • Correlate with DNA methylation profiles at NFE4 target loci

  • Integrate with chromatin accessibility data (ATAC-seq, DNase-seq)

• Methodology for Integration:

  • Use coincident peak analysis to identify regions where NFE4 binding correlates with specific epigenetic marks

  • Perform sequential ChIP to detect co-occurrence of NFE4 and specific histone modifications

  • Employ machine learning approaches to identify epigenetic signatures associated with acetylated NFE4 binding

• Functional Validation:

  • Use CRISPR/Cas9 to mutate NFE4 binding sites and assess effects on chromatin state

  • Employ epigenome editing to modify specific marks at NFE4 target loci

  • Correlate changes in NFE4 acetylation with chromatin reorganization during erythroid differentiation

This integrated approach can provide a systems-level understanding of how NFE4 acetylation contributes to the epigenetic regulation of gene expression in erythroid cells.